SEGMENT INFORMATION (Summary of Reportable Segments) (Details) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020 USD ($)	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Sep. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2020 USD ($) segment	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Financial information regarding the Company's reportable segments
Number of reportable segments | segment									3
Net sales	$ 749,329	$ 759,153	$ 699,305	$ 721,553	$ 671,333	$ 701,278	$ 742,661	$ 744,460	$ 2,929,340	$ 2,859,732	$ 2,764,761
Acquisition-related costs									(6,087)	(3,927)	(23,770)
Restructuring initiatives									(26,492)	(20,472)	(63,829)
Depreciation and amortization									(220,300)	(194,552)	(171,747)
Interest expense									(33,244)	(35,489)	(32,626)
Interest income									958	4,174	7,056
Income before Income Taxes									301,155	342,069	266,020
Capital expenditures									245,954	242,276	211,252
Total Assets	3,990,053				3,562,119				3,990,053	3,562,119	3,377,735
Pharma
Financial information regarding the Company's reportable segments
Net sales									1,225,779	1,091,051	954,652
Adjusted EBITDA									428,469	387,483	343,706
Restructuring initiatives									(220)	(632)	(3,589)
Depreciation and amortization									(75,874)	(65,590)	(51,495)
Capital expenditures									117,835	89,702	54,433
Total Assets	1,549,781				1,422,815				1,549,781	1,422,815	1,324,696
Beauty + Home
Financial information regarding the Company's reportable segments
Net sales									1,298,151	1,352,714	1,426,382
Adjusted EBITDA									129,299	181,150	185,926
Restructuring initiatives									(24,464)	(17,682)	(52,244)
Depreciation and amortization									(95,880)	(82,778)	(83,546)
Capital expenditures									93,980	96,040	101,371
Total Assets	1,610,058				1,378,292				1,610,058	1,378,292	1,373,816
Corporate & Other
Financial information regarding the Company's reportable segments
Adjusted EBITDA									(43,443)	(44,406)	(36,285)
Restructuring initiatives									95	(1,767)	(3,811)
Depreciation and amortization									(10,778)	(10,456)	(9,239)
Capital expenditures									15,690	13,933	25,739
Transfer of Corporate Technology Expenditures									(11,507)	(2,529)	(11,527)
Total Assets	280,944				226,485				280,944	226,485	177,523
Food + Beverage
Financial information regarding the Company's reportable segments
Net sales									405,410	415,967	383,727
Adjusted EBITDA									71,995	68,108	57,589
Restructuring initiatives									(1,903)	(391)	(4,185)
Depreciation and amortization									(37,768)	(35,728)	(27,467)
Capital expenditures									29,956	45,130	41,236
Total Assets	$ 549,270				$ 534,527				549,270	534,527	501,700
Operating segment
Financial information regarding the Company's reportable segments
Net sales									2,962,530	2,894,507	2,787,989
Operating segment | Pharma
Financial information regarding the Company's reportable segments
Net sales									1,234,107	1,100,463	955,069
Operating segment | Beauty + Home
Financial information regarding the Company's reportable segments
Net sales									1,320,988	1,376,027	1,446,231
Operating segment | Food + Beverage
Financial information regarding the Company's reportable segments
Net sales									407,435	418,017	386,689
Intersegment
Financial information regarding the Company's reportable segments
Net sales									(33,190)	(34,775)	(23,228)
Intersegment | Pharma
Financial information regarding the Company's reportable segments
Net sales									(8,328)	(9,412)	(417)
Intersegment | Beauty + Home
Financial information regarding the Company's reportable segments
Net sales									(22,837)	(23,313)	(19,849)
Intersegment | Food + Beverage
Financial information regarding the Company's reportable segments
Net sales									$ (2,025)	$ (2,050)	$ (2,962)